Editas Medicine, Inc. (EDIT)
2.17
+0.03
(+1.40%)
USD |
NASDAQ |
Nov 13, 16:00
2.165
0.00 (0.00%)
After-Hours: 19:59
Editas Medicine Enterprise Value : 214.00M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 214.00M |
| November 12, 2026 | 209.39M |
| November 11, 2026 | 246.27M |
| November 10, 2026 | 265.48M |
| November 09, 2026 | 303.12M |
| November 06, 2026 | 275.46M |
| November 05, 2026 | 272.39M |
| November 04, 2026 | 298.51M |
| November 03, 2026 | 280.07M |
| November 02, 2026 | 275.46M |
| October 30, 2026 | 290.83M |
| October 29, 2026 | 330.78M |
| October 28, 2026 | 333.85M |
| October 27, 2026 | 280.07M |
| October 26, 2026 | 249.34M |
| October 23, 2026 | 249.34M |
| October 22, 2026 | 263.17M |
| October 21, 2026 | 266.24M |
| October 20, 2026 | 277.00M |
| October 19, 2026 | 252.42M |
| October 16, 2026 | 241.66M |
| October 15, 2026 | 255.49M |
| October 14, 2026 | 229.37M |
| October 13, 2026 | 256.26M |
| October 12, 2026 | 303.12M |
| Date | Value |
|---|---|
| October 09, 2026 | 326.17M |
| October 08, 2026 | 316.95M |
| October 07, 2026 | 303.12M |
| October 06, 2026 | 300.05M |
| October 05, 2026 | 309.27M |
| October 02, 2026 | 283.15M |
| October 01, 2026 | 267.78M |
| September 30, 2026 | 275.46M |
| September 29, 2026 | 257.25M |
| September 28, 2026 | 244.97M |
| September 25, 2026 | 255.71M |
| September 24, 2026 | 281.81M |
| September 23, 2026 | 272.60M |
| September 22, 2026 | 307.91M |
| September 21, 2026 | 294.10M |
| September 18, 2026 | 274.14M |
| September 17, 2026 | 277.21M |
| September 16, 2026 | 275.67M |
| September 15, 2026 | 263.39M |
| September 14, 2026 | 280.28M |
| September 11, 2026 | 274.14M |
| September 10, 2026 | 266.46M |
| September 09, 2026 | 284.88M |
| September 08, 2026 | 324.80M |
| September 04, 2026 | 355.51M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Vertex Pharmaceuticals, Inc. | 136.71B |
| Recursion Pharmaceuticals, Inc. | 1.305B |
| Halozyme Therapeutics, Inc. | 13.60B |
| Novavax, Inc. | 1.079B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.39M |
| Revenue (Quarterly) | 10.36M |
| Total Expenses (Quarterly) | 33.76M |
| EPS Diluted (Quarterly) | -0.1523 |
| Gross Profit Margin (Quarterly) | 96.29% |
| Profit Margin (Quarterly) | -225.7% |
| Earnings Yield | -28.48% |
| Normalized Earnings Yield | -30.92 |